• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Galapagos Receives Transparency Notifications from Bank of America

    11/26/25 1:30:00 AM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GLPG alert in real time by email

    Mechelen, Belgium; November 26, 2025, 07:30 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received transparency notifications from Bank of America.

    Pursuant to Belgian transparency legislation1, Galapagos received transparency notifications on November 18 and November 19, 2025, from Bank of America Corporation indicating that it positively crossed the threshold of 5% of Galapagos' voting rights on November 12, 2025 following an acquisition of Galapagos' voting rights and equivalent financial instruments, and then subsequently fell below this threshold on November 14, 2025 following the disposal of such instruments.

    On November 14, 2025, the Bank of America Corporation (taking into account the holding of its affiliates) owned 103,534 voting rights and 2,159,259 equivalent financial instruments, representing together 3.43% of Galapagos' currently outstanding 65,897,071 shares, versus 168,924 voting rights and 3,295,951 equivalent financial instruments, representing together 5.26%, in the previous notification.

    Summary of the transactions:

    Date on which the threshold was crossedDate of notificationDirect voting rights after the transactionEquivalent financial instruments after the transactionTotal
    November 12, 2025November 18, 20250.26%5.00%5.26%
    November 14, 2025November 19, 20250.16%3.28%3.43%

    Content of the notifications from Bank of America Corporation:

    The notification dated November 19, 2025 contains the following information:

    • Date of notification: November 19, 2025
    • Date on which the threshold is crossed: November 14, 2025
    • Threshold of voting rights crossed downwards (in %): 5%
    • Notification by: Bank of America Corporation
    • Denominator: 65,897,071
    • Reason for the notification: Acquisition or disposal of financial instruments that are treated as voting securities
    • Notified details:



    A) Voting RightsPrevious notificationAfter the transaction
     # of voting rights# of voting rights% of voting rights
    Holder of voting rights Linked to securitiesNot linked to securitiesLinked to securitiesNot linked to securities
    Bank of America Corporation00 0.00% 
    Bank of America, National Association12,56812,476 0.02% 
    Merrill Lynch International65,07066,430 0.10% 
    Managed Account Advisors LLC33 0.00% 
    BofA Securities, Inc.76,70010,042 0.02% 
    Merrill Lynch, Pierce, Fenner & Smith

    Incorporated
    14,46214,462 0.02% 
    U.S. Trust Company of Delaware121121 0.00% 
    Subtotal168,924103,534 0.16% 
     TOTAL103,53400.16%0.00%



    B) Equivalent financial instruments After the transaction
    Holder of equivalent financial instrumentsType of financial instrumentExpiration dateExercise period or date# of voting rights that may be acquired if the instrument is exercised% of voting rightsSettlement
    Merrill Lynch InternationalRight to Recall  195,5330.30%physical
    BofA Securities, Inc.Rights of Use  1,796,9752.73%physical
    Merrill Lynch InternationalRights of Use  8,6790.01%physical
    Merrill Lynch InternationalPhysical Call Option19/06/2026 100,0000.15%physical
    Bank of America, National AssociationSwaps15/10/2027 270.00%cash
    Bank of America, National AssociationSwaps15/06/2026 12,5000.02%cash
    Merrill Lynch InternationalSwaps30/04/2026 18,7900.03%cash
    Merrill Lynch InternationalSwaps02/07/2026 7170.00%cash
    Merrill Lynch InternationalSwaps15/10/2027 270.00%cash
    Merrill Lynch InternationalSwaps01/11/2027 1620.00%cash
    Merrill Lynch InternationalSwaps15/06/2026 12,5000.02%cash
    Merrill Lynch InternationalSwaps30/01/2026 1690.00%cash
    Merrill Lynch InternationalSwaps17/11/2025 12,5210.02%cash
    Merrill Lynch InternationalSwaps28/08/2026 6590.00%cash
     TOTAL  2,159,2593.28% 



    TOTAL (A&B)# of voting rights% of voting rights
     2,262,7933.43%

    The chain of control has been described at the end of the notification (section 11) and can be found here.

    The notification dated November 18, 2025 contains the following information:

    • Date of notification: November 18, 2025
    • Date on which the threshold is crossed: November 12, 2025
    • Threshold of voting rights crossed upwards (in %): 5%
    • Notification by: Bank of America Corporation
    • Denominator: 65,897,071
    • Reason for the notification: Acquisition or disposal of voting securities or voting rights and acquisition or disposal of financial instruments that are treated as voting securities
    • Notified details:



    A) Voting RightsPrevious notificationAfter the transaction
     # of voting rights# of voting rights% of voting rights
    Holder of voting rights Linked to securitiesNot linked to securitiesLinked to securitiesNot linked to securities
    Bank of America Corporation 000.00%0.00%
    Bank of America, National Association 12,56800.02%0.00%
    Merrill Lynch International 65,07000.10%0.00%
    Managed Account Advisors LLC 300.00%0.00%
    BofA Securities, Inc. 76,70000.12%0.00%
    Merrill Lynch, Pierce, Fenner & Smith

    Incorporated
     14,46200.02%0.00%
    U.S. Trust Company of Delaware 12100.00%0.00%
    Subtotal 168,924 0.26% 
     TOTAL168,92400.26%0.00%



    B) Equivalent financial instruments After the transaction
    Holder of equivalent financial instrumentsType of financial instrumentExpiration dateExercise period or date# of voting rights that may be acquired if the instrument is exercised% of voting rightsSettlement
    Merrill Lynch InternationalRight to Recall  196,4910.30%physical
    BofA Securities, Inc.Rights of Use  2,936,4524.46%physical
    Merrill Lynch InternationalRights of Use  4,0890.01%physical
    Merrill Lynch InternationalPhysical Call Option19/06/2026 100,0000.15%physical
    Merrill Lynch InternationalSwaps30/04/2026 19,2200.03%cash
    Bank of America, National AssociationSwaps15/06/2026 12,5000.02%cash
    Merrill Lynch InternationalSwaps02/07/2026 7440.00%cash
    Merrill Lynch InternationalSwaps15/06/2026 12,5000.02%cash
    Merrill Lynch InternationalSwaps30/01/2026 1,4340.00%cash
    Merrill Lynch InternationalSwaps17/11/2025 12,5210.02%cash
     TOTAL  3,295,9515.00% 



    TOTAL (A&B)# of voting rights% of voting rights
     3,364,8755.26%

    The chain of control has been described at the end of the notification (section 11) and can be found here.

    For further information, contact Galapagos:

    Investor Relations

    Glenn Schulman

    +1 412 522 6239

    [email protected]

    Corporate Communications

    Marieke Vermeersch

    +32 479 490 603

    [email protected]

    Visit us at www.glpg.com or follow us on LinkedIn or X.


    1 Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions, as amended from time to time.

    Attachments

    • Galapagos Receives Transparency Notifications from Bank of America
    • GALAPAGOS NV Form TD 14.11.2025_Revised Part I
    • GALAPAGOS NV Form TD 12.11.2025_Part I_Revision2


    Primary Logo

    Get the next $GLPG alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GLPG

    DatePrice TargetRatingAnalyst
    10/22/2025$40.00Market Perform → Outperform
    Leerink Partners
    8/5/2025Hold → Sell
    Deutsche Bank
    2/14/2025$31.00 → $22.00Equal-Weight → Underweight
    Morgan Stanley
    11/20/2024Hold → Reduce
    Kepler
    9/9/2024$24.00Market Perform
    Leerink Partners
    8/2/2024Outperform → Mkt Perform
    Raymond James
    3/28/2024$41.00 → $31.00Neutral → Underperform
    BofA Securities
    3/7/2024$38.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $GLPG
    SEC Filings

    View All

    SEC Form 6-K filed by Galapagos NV

    6-K - GALAPAGOS NV (0001421876) (Filer)

    11/26/25 6:05:05 AM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Galapagos NV

    6-K - GALAPAGOS NV (0001421876) (Filer)

    11/6/25 6:00:22 AM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Galapagos NV

    6-K - GALAPAGOS NV (0001421876) (Filer)

    11/3/25 5:04:12 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLPG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Galapagos Receives Transparency Notifications from Bank of America

    Mechelen, Belgium; November 26, 2025, 07:30 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received transparency notifications from Bank of America. Pursuant to Belgian transparency legislation1, Galapagos received transparency notifications on November 18 and November 19, 2025, from Bank of America Corporation indicating that it positively crossed the threshold of 5% of Galapagos' voting rights on November 12, 2025 following an acquisition of Galapagos' voting rights and equivalent financial instruments, and then subsequently fell below this threshold on November 14, 2025 following the disposal of such instruments. On November 14, 2025, the Bank of America Corporat

    11/26/25 1:30:00 AM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos Reports Nine Months 2025 Financial Results and Provides Business Update

    Strategic review process concluded with intention to wind down cell therapy business, representing optimal capital allocation pathway to support a stronger and sustainable future for GalapagosContinued evolution of leadership team aligned with strategic directionRobust balance sheet with €3.05 billion in cash and financial investments as of September 30, 2025; year-end 2025 cash position expected at €2.975 billion to €3.025 billion   Management to host a conference call tomorrow, November 6, 2025, at 14:00 CET / 08:00 AM ET Mechelen, Belgium; November 5, 2025, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced its financial results for the first nine m

    11/5/25 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos to Present New Data from Cell Therapy Program at ASH 2025

    Oral presentation of GLPG5101 data from the ATALANTA-1 study in patients with high-risk relapsed/refractory mantle cell lymphoma Two abstracts featuring new Phase 2 data highlight the potential of CAR-T cell therapy candidate, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma Results demonstrate high rates of complete and durable responses along with low rates of high-grade toxicities using GLPG5101 manufactured on innovative median seven-day vein-to-vein time platform, potentially enabling broader access to cell therapy Mechelen, Belgium; November 3, 2025, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that it will present new and updated data for CAR T-cell ther

    11/3/25 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLPG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Galapagos NV upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Galapagos NV from Market Perform to Outperform and set a new price target of $40.00

    10/22/25 7:00:32 AM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos NV downgraded by Deutsche Bank

    Deutsche Bank downgraded Galapagos NV from Hold to Sell

    8/5/25 3:22:16 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos NV downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Galapagos NV from Equal-Weight to Underweight and set a new price target of $22.00 from $31.00 previously

    2/14/25 8:06:36 AM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLPG
    Leadership Updates

    Live Leadership Updates

    View All

    Galapagos Announces Changes to its Board to Accelerate Strategic Focus on Business Development

    New Directors bring strong financial leadership, capital allocation, and business development expertise to the Board Mechelen, Belgium; October 30, 2025, 21:01 CET — Galapagos NV ((Euronext &, NASDAQ:GLPG), today announced several changes to its Board of Directors as part of its ongoing commitment to long-term governance and strategic continuity. These changes strengthen the alignment of the Board's composition with the Company's strategic direction and support its focus on transformational business development to build a pipeline of novel medicines in areas of high unmet medical need. Seasoned biopharma executive Dr. Neil Johnston has been appointed to the Board of Directors by way of co-

    10/30/25 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos Announces Appointment of Fred Blakeslee as General Counsel

    Mechelen, Belgium; October 16, 2025, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointment of Mr. Fred Blakeslee as Executive Vice President and General Counsel effective October 16, 2025. Blakeslee is succeeding Ms. Valeria Cnossen, who will leave the Company after a short transition period. "We are very pleased to welcome Fred to the executive team," said Henry Gosebruch, CEO of Galapagos. "He brings a unique combination of top-tier legal expertise, global business transaction experience, and deep strategic understanding of the biopharma ecosystem. His proven track record of negotiating complex, high-impact partnerships and acquisitions, and fostering cross-f

    10/16/25 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business Transformation

    Appoints Sooin Kwon as Chief Business Officer and Dan Grossman as Chief Strategy Officer Both executives possess proven track records in strategic execution and deal-making and will help drive long-term value creation at Galapagos Mechelen, Belgium; July 23, 2025, 22.01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointments of Ms. Sooin Kwon as Chief Business Officer (CBO) and Mr. Dan Grossman as Chief Strategy Officer (CStO), effective August 4, 2025, further strengthening the Company's leadership team. They will both report to Henry Gosebruch, CEO, and join the Company's Management Committee. "We are excited to welcome Sooin and Dan to our senior leadership," said

    7/23/25 4:03:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLPG
    Financials

    Live finance-specific insights

    View All

    Galapagos Reports Nine Months 2025 Financial Results and Provides Business Update

    Strategic review process concluded with intention to wind down cell therapy business, representing optimal capital allocation pathway to support a stronger and sustainable future for GalapagosContinued evolution of leadership team aligned with strategic directionRobust balance sheet with €3.05 billion in cash and financial investments as of September 30, 2025; year-end 2025 cash position expected at €2.975 billion to €3.025 billion   Management to host a conference call tomorrow, November 6, 2025, at 14:00 CET / 08:00 AM ET Mechelen, Belgium; November 5, 2025, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced its financial results for the first nine m

    11/5/25 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts

    First U.S. patient dosed in ATALANTA-1 study of GLPG5101 Mantle cell lymphoma (MCL), a high-unmet-need hematological malignancy, selected as lead indication for the GLPG5101 program; Pivotal development planned to start in 2026 and aiming for approval in 2028 Executive leadership changes with Dr. Paul Stoffels retiring as CEO upon appointment of his successor while continuing as Chair of the Board, Thad Huston departing as CFO/COO on August 1, 2025, and Henry Gosebruch appointed Founding CEO of Galapagos subsidiary SpinCo €3.3 billion in cash and financial investments as of March 31, 2025; Normalized annual cash burn guidance, excluding restructuring costs, in the range of €175 million -

    4/23/25 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update

    Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein Focusing on accelerating GLPG5101 program, expanding to eight indications with significant unmet needs, and aiming for first approval by 2028 Plan to separate into two companies listed on Nasdaq and Euronext, with SpinCo to build a pipeline through deals and Galapagos to advance novel cell therapies for cancers of high unmet need Management to host conference call tomorrow, February 13, 2025, at 14:00 CET / 8:00 am ET Mechelen, Belgium; February 12, 2025, 22:01 CET; regulated information – G

    2/12/25 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLPG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Galapagos NV

    SC 13G/A - GALAPAGOS NV (0001421876) (Subject)

    11/12/24 9:55:16 AM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Galapagos NV

    SC 13D/A - GALAPAGOS NV (0001421876) (Subject)

    10/8/24 4:35:06 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Galapagos NV

    SC 13D - GALAPAGOS NV (0001421876) (Subject)

    8/23/24 4:01:26 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care